Vivianne Malmström Selected Research

Systemic Lupus Erythematosus (Libman-Sacks Disease)

1/2022	Rheumatoid Factor and Anti-Modified Protein Antibody Reactivities Converge on IgG Epitopes.
1/2022	Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.
1/2021	First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis.
2/2019	B cell alterations during BAFF inhibition with belimumab in SLE.
4/2017	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
1/2006	Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vivianne Malmström Research Topics

Disease

58	Rheumatoid Arthritis 01/2022 - 01/2006
14	Inflammation (Inflammations) 11/2022 - 08/2008
9	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2006
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2006
6	Arthritis (Polyarthritis) 12/2018 - 06/2002
5	Pain (Aches) 01/2022 - 04/2016
5	Myositis (Idiopathic Inflammatory Myopathies) 01/2020 - 12/2012
3	Lupus Nephritis 01/2016 - 01/2015
2	Hypersensitivity (Allergy) 01/2022 - 06/2005
2	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2021 - 11/2020
2	Nephritis 01/2021 - 02/2015
2	Arthralgia (Joint Pain) 04/2016 - 07/2013
2	Necrosis 10/2014 - 01/2006
2	Experimental Arthritis 07/2014 - 06/2002
1	Edema (Dropsy) 01/2022
1	Periodontitis 01/2022
1	Rheumatic Diseases (Rheumatism) 01/2022
1	Synovitis 01/2022
1	Spondylarthropathies 01/2022
1	Atherosclerosis 05/2021
1	Serum Sickness 01/2021
1	Human Influenza (Influenza) 01/2021
1	Antisynthetase syndrome 01/2020
1	Polymyositis 01/2019
1	Dermatomyositis (Dermatopolymyositis) 01/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018
1	Fatigue 04/2017
1	Ankylosing Spondylitis 12/2016
1	Psoriatic Arthritis 12/2016
1	Myotoxicity 01/2016

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2008
21	AutoantibodiesIBA 01/2022 - 10/2012
19	AntibodiesIBA 01/2022 - 01/2007
15	Anti-Citrullinated Protein AntibodiesIBA 01/2022 - 01/2010
13	acetyl 4-aminosalicylic acidIBA 10/2020 - 01/2010
10	Peptides (Polypeptides)IBA 01/2022 - 12/2009
9	Immunoglobulin G (IgG)IBA 01/2022 - 01/2007
9	AntigensIBA 01/2022 - 08/2008
8	AutoantigensIBA 01/2020 - 08/2008
7	EpitopesIBA 01/2022 - 06/2002
7	CitrullineIBA 01/2022 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 12/2018 - 07/2013
6	Collagen Type II (Type II Collagen)IBA 01/2016 - 06/2002
4	HLA-DRB1 Chains (HLA DRB1)IBA 01/2022 - 12/2009
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 06/2002
4	Phosphopyruvate Hydratase (Enolase)IBA 01/2017 - 08/2008
3	Monoclonal AntibodiesIBA 01/2022 - 01/2019
3	Rituximab (Mabthera)FDA Link 01/2022 - 01/2006
3	serum P-component (CIt)IBA 12/2021 - 01/2016
3	HLA-DR Antigens (HLA-DR)IBA 01/2018 - 03/2013
3	ChemokinesIBA 02/2017 - 04/2016
3	HLA-DRB1*04:01 antigenIBA 01/2017 - 10/2011
3	Interleukin-17 (Interleukin 17)IBA 02/2015 - 01/2011
3	LigandsIBA 01/2015 - 01/2006
2	RNA (Ribonucleic Acid)IBA 11/2022 - 09/2016
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2021
2	EnzymesIBA 01/2022 - 01/2011
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2021 - 11/2010
2	TenascinIBA 12/2021 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 04/2017
2	Rheumatoid FactorIBA 01/2021 - 01/2017
2	Immunoglobulin A (IgA)IBA 01/2021 - 07/2017
2	Interleukin-2 (IL2)IBA 01/2021 - 01/2020
2	Messenger RNA (mRNA)IBA 12/2019 - 10/2014
2	Abatacept (Orencia)FDA Link 01/2019 - 08/2013
2	Fibrinogen (Factor I)FDA Link 12/2016 - 01/2010
2	B-Cell Activating FactorIBA 01/2015 - 10/2014
2	CytokinesIBA 10/2014 - 08/2011
1	Acid Sensing Ion ChannelsIBA 01/2022
1	Analgesics (Analgesic Drugs)IBA 01/2022
1	ImmunosorbentsIBA 01/2022
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2022
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2022
1	Secretory Phospholipases A2IBA 01/2022
1	homocitrullineIBA 01/2022
1	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 01/2021
1	Extracellular Matrix ProteinsIBA 01/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Myeloblastin (Proteinase 3)IBA 11/2020
1	CD40 Ligand (CD40L)IBA 01/2020
1	InterferonsIBA 01/2020
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2020
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2018
1	Non-Receptor Type 2 Protein Tyrosine PhosphataseIBA 01/2018
1	Malondialdehyde (Propanedial)IBA 11/2017
1	Immunoglobulins (Immunoglobulin)IBA 08/2017
1	IgA receptor (protein B)IBA 07/2017
1	Fc Receptors (Fc Receptor)IBA 07/2017
1	Biological ProductsIBA 04/2017
1	Prostaglandins AIBA 04/2017
1	belimumabIBA 04/2017
1	Interleukin-8 (Interleukin 8)IBA 02/2017
1	DNA (Deoxyribonucleic Acid)IBA 09/2016
1	reparixinIBA 04/2016
1	PerforinIBA 01/2016
1	fluorexon (calcein)IBA 01/2016
1	Antiphospholipid AntibodiesIBA 01/2016

Therapy/Procedure

7	Therapeutics 01/2021 - 01/2011
1	Retreatment 01/2021
1	Aftercare (After-Treatment) 02/2015